264 related articles for article (PubMed ID: 32472959)
21. Rapamycin restores peripheral blood flow in aged mice and in mouse models of atherosclerosis and Alzheimer's disease.
Van Skike CE; DeRosa N; Galvan V; Hussong SA
Geroscience; 2023 Jun; 45(3):1987-1996. PubMed ID: 37052770
[TBL] [Abstract][Full Text] [Related]
22. Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer's disease with and without cerebrovascular disease.
Ji F; Pasternak O; Liu S; Loke YM; Choo BL; Hilal S; Xu X; Ikram MK; Venketasubramanian N; Chen CL; Zhou J
Alzheimers Res Ther; 2017 Aug; 9(1):63. PubMed ID: 28818116
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's disease in late-life dementia: a minor toxic consequence of devastating cerebrovascular dysfunction.
Henry-Feugeas MC
Med Hypotheses; 2008; 70(4):866-75. PubMed ID: 17825499
[TBL] [Abstract][Full Text] [Related]
24. [Roles of Mammalian Target of Rapamycin Signaling and Autophagy Pathway in Alzheimer's Disease].
Chang YF; Hu WM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Apr; 41(2):248-255. PubMed ID: 31060682
[TBL] [Abstract][Full Text] [Related]
25. Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies.
Tramutola A; Lanzillotta C; Di Domenico F
Expert Rev Neurother; 2017 Jan; 17(1):33-45. PubMed ID: 27690737
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.
Spilman P; Podlutskaya N; Hart MJ; Debnath J; Gorostiza O; Bredesen D; Richardson A; Strong R; Galvan V
PLoS One; 2010 Apr; 5(4):e9979. PubMed ID: 20376313
[TBL] [Abstract][Full Text] [Related]
27. Intranasal Insulin Increases Synaptic Protein Expression and Prevents Anesthesia-Induced Cognitive Deficits Through mTOR-eEF2 Pathway.
Yu Q; Dai CL; Zhang Y; Chen Y; Wu Z; Iqbal K; Liu F; Gong CX
J Alzheimers Dis; 2019; 70(3):925-936. PubMed ID: 31306126
[TBL] [Abstract][Full Text] [Related]
28. Small Vessel Cerebrovascular Pathology Identified by Magnetic Resonance Imaging Is Prevalent in Alzheimer's Disease and Mild Cognitive Impairment: A Potential Target for Intervention.
Scott TM; Bhadelia RA; Qiu WQ; Folstein MF; Rosenberg IH
J Alzheimers Dis; 2018; 65(1):293-302. PubMed ID: 30040728
[TBL] [Abstract][Full Text] [Related]
29. Activation of mTOR signaling leads to orthopedic surgery-induced cognitive decline in mice through β-amyloid accumulation and tau phosphorylation.
Shen W; Lu K; Wang J; Wu A; Yue Y
Mol Med Rep; 2016 Oct; 14(4):3925-34. PubMed ID: 27599409
[TBL] [Abstract][Full Text] [Related]
30. Role of age-related alterations of the cerebral venous circulation in the pathogenesis of vascular cognitive impairment.
Fulop GA; Tarantini S; Yabluchanskiy A; Molnar A; Prodan CI; Kiss T; Csipo T; Lipecz A; Balasubramanian P; Farkas E; Toth P; Sorond F; Csiszar A; Ungvari Z
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1124-H1140. PubMed ID: 30848677
[TBL] [Abstract][Full Text] [Related]
31. Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease.
Goldwaser EL; Acharya NK; Sarkar A; Godsey G; Nagele RG
J Alzheimers Dis; 2016 Sep; 54(2):445-56. PubMed ID: 27497477
[TBL] [Abstract][Full Text] [Related]
32. URB597 improves cognitive impairment induced by chronic cerebral hypoperfusion by inhibiting mTOR-dependent autophagy.
Wang D; Lin Q; Su S; Liu K; Wu Y; Hai J
Neuroscience; 2017 Mar; 344():293-304. PubMed ID: 28042028
[TBL] [Abstract][Full Text] [Related]
33. The Role of Methionine-Rich Diet in Unhealthy Cerebrovascular and Brain Aging: Mechanisms and Implications for Cognitive Impairment.
Ungvari A; Gulej R; Csik B; Mukli P; Negri S; Tarantini S; Yabluchanskiy A; Benyo Z; Csiszar A; Ungvari Z
Nutrients; 2023 Nov; 15(21):. PubMed ID: 37960316
[TBL] [Abstract][Full Text] [Related]
34. Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease.
Manukhina EB; Downey HF; Shi X; Mallet RT
Exp Biol Med (Maywood); 2016 Jun; 241(12):1351-63. PubMed ID: 27190276
[TBL] [Abstract][Full Text] [Related]
35. mTOR in cerebrovascular disease.
Van Skike CE; Galvan V
Aging (Albany NY); 2019 Mar; 11(5):1331-1332. PubMed ID: 30867339
[No Abstract] [Full Text] [Related]
36. Geniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer's disease.
Zhang Z; Wang X; Zhang D; Liu Y; Li L
Aging (Albany NY); 2019 Jan; 11(2):536-548. PubMed ID: 30684442
[TBL] [Abstract][Full Text] [Related]
37. The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging.
de la Torre J
J Alzheimers Dis; 2018; 63(1):35-52. PubMed ID: 29614675
[TBL] [Abstract][Full Text] [Related]
38. Chronic kidney disease accelerates cognitive impairment in a mouse model of Alzheimer's disease, through angiotensin II.
Nakagawa T; Hasegawa Y; Uekawa K; Kim-Mitsuyama S
Exp Gerontol; 2017 Jan; 87(Pt A):108-112. PubMed ID: 27916702
[TBL] [Abstract][Full Text] [Related]
39. Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease.
Yates SC; Zafar A; Hubbard P; Nagy S; Durant S; Bicknell R; Wilcock G; Christie S; Esiri MM; Smith AD; Nagy Z
Acta Neuropathol Commun; 2013 May; 1():3. PubMed ID: 24252508
[TBL] [Abstract][Full Text] [Related]
40. Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications.
Kumar Nelson V; Jha NK; Nuli MV; Gupta S; Kanna S; Gahtani RM; Hani U; Singh AK; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Al Othaim A; Begum SS; Ahmad F; Mishra PC; Jha SK; Ojha S
Ageing Res Rev; 2024 Jul; 98():102224. PubMed ID: 38346505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
